GRC17536, another TRPA1 antagonist, showed promise in reducing pain scores in patients with painful diabetic polyneuropathy, highlighting the potential clinical benefits of targeting TRPA1 for pain management [314]. This evidence concerns the gene TRPA1 and diabetic neuropathy.